Loading stock data…
HeartBeam (BEAT)
$0.65-0.02 (-3.27%)
After Hours$0.66+0.00 (+0.26%)· Last close Jun 29
HeartBeam, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
HeartBeam, Inc. in the Healthcare sector is trading at $0.65 with a market capitalization of $42M. Wall Street consensus targets $3.83 (3 analysts), implying a +486.8% move over the next 12 months. The stock is currently near its 52-week low of $0.54, remaining 54.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +486.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 26) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.72M↑ | -$5.31M↓ | -$5.29M↓ | -$5.04M↑ | -$5.50M |
| Net Income | -$4.70M↑ | -$5.30M↓ | -$5.25M↓ | -$4.97M↑ | -$5.48M |
Peer Comparison
JNJUNHPFE
Fundamentals
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartB...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$41.91M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-3185.98%
Volume
Today's trading volume
332,529
Recent News
HeartBeam (BEAT) Stock Sees Fair Value Cut As Analysts Weigh Dilution And Slower Ramp
HeartBeam’s latest analyst update centers on a reduced fair value estimate, with the central value per share moving from about US$5.08 to US$3.83. Research commentary links these cuts to tempered expectations around the pace of the revenue ramp and the impact of recent equity offerings, even as some analysts still point to longer term execution potential and a solid Q1 update. As you read on, you will see how these shifting targets and the research behind them can help you track the evolving...
Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Insiders are betting big on three stocks. Board members, CEOs, and CFOs are among the buyers, signalling confidene in their fundamentals.
HeartBeam (BEAT) Upgraded to Buy: Here's What You Should Know
HeartBeam (BEAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
HeartBeam, Inc. Q1 2026 Earnings Call Summary
Moby summary of HeartBeam, Inc.'s Q1 2026 earnings call
HeartBeam Inc (BEAT) Q1 2026 Earnings Call Highlights: Strategic Partnerships and Financial ...
HeartBeam Inc (BEAT) advances its market presence with key partnerships and robust financing, despite early-stage commercialization challenges.